INBX vs MAZE
INBX: A clinical-stage biopharma company leveraging proprietary protein engineering to develop next-generation biologic therapeutics for hard-to-treat solid tumors. MAZE: Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease indications.
Side-by-side fundamentals
| Metric | INBX | MAZE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $85.92 | $28.49 | |
| Market cap as of 2026-07-23 | $1.3B | $1.6B | |
| Net margin as of 2026-07-23 | -5465.6% | +11.0% | MAZE higher |
| Operating margin as of 2026-07-23 | -5522.6% | +34.4% | MAZE higher |
| ROE as of 2026-07-23 | -269.6% | -36.6% | MAZE higher |
| ROA as of 2026-07-23 | -72.3% | -31.8% | MAZE higher |
| Debt / equity as of 2026-07-23 | 12.58 | 0.11 | MAZE lower |
| Revenue growth (YoY) as of 2026-07-23 | +550.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -15.0% | n/a | |
| Beta as of 2026-07-23 | 2.92 | 1.10 | |
| 1-year return as of 2026-07-22 close | +296.1% | +75.9% | INBX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.